Business
-
Vast Therapeutics (formerly Novoclem) has announced that Shionogi & Co. was the sole investor in a Series A financing round that will fund pre-clinical and Phase 1 development of the company’s dry powder nitric oxide… Read more . . .
-
US Pharmaceutical company Neurelis, which recently submitted an NDA for Valtoco diazepam nasal spray, has acquired Aegis Therapeutics and its Intravail transmucosal absorption technology, a component of the Valtoco formulation. In addition to Intravail, Aegis… Read more . . .
-
Vectura has announced that a Phase 3 study of VR475 budesonide inhalation suspension for the treatment of severe uncontrolled asthma in adult and adolescent patients failed to meet its primary endpoint. As a result, the… Read more . . .
-
InCarda Therapeutics has announced the completion of an oversubscribed $42 million Series B financing that will fund a Phase 2 study of InRhythm inhaled flecainide for the treatment of recent-onset paroxysmal atrial fibrillation (PAF). The… Read more . . .
-
Vectura and Hikma Pharmaceuticals have announced a deal for development and commercialization of generic versions of GSK’s Ellipta dry powder inhalers. Hikma will pay Vectura $15 million up front, $5 million at the start of… Read more . . .
-
AstraZeneca has announced that Covis Pharma will pay $350 million up front for the rights to market Alvesco ciclesonide MDI and the ciclesonide nasal spray Omnaris and nasal MDI Zetonna outside of the US. The… Read more . . .
-
Receptor Life Sciences has raised $29 million for development of several cannabinoid products, the company said. In 2016, MannKind Corporation announced that it had licensed its dry powder inhalation technology to Receptor, which was then… Read more . . .
-
Glenmark Pharmaceuticals has officially opened its first US manufacturing site in Monroe, North Carolina, the company said. The 100,000 sq ft, $100 million facility will eventually produce hundreds of millions of doses in various forms… Read more . . .
-
According to the Scottish government, a new manufacturing facility built by GSK in Montrose to produce APIs for its Ellipta dry powder inhalers officially opened on October 22, 2018, with Scottish First Minister Nicola Sturgeon… Read more . . .
-
Perrigo said that Adapt Pharma and Opiant Pharmaceuticals have initiated patent litigation in the United States District Court for the District of New Jersey in regards to Perrigo’s recently filed ANDA for a generic version… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden